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Hans Wedel, PHD,‡ Norm R. C. Campbell, MD,§ on behalf of the ASCOT Investigators
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Objectives The aim of this study was to evaluate the effect of baseline heart rate on the efficacy of atenolol-based com-
pared with amlodipine-based therapy in patients with hypertension uncomplicated by coronary heart disease in
the ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm).
Background Heart rate is an established risk factor for cardiovascular events. Consequently, it is a widely held belief that
beta-blockers should be prescribed for management of hypertension in patients with higher heart rates.
Methods Patients with atrial fibrillation or taking rate-limiting antihypertensive drugs at baseline were excluded. Primary
analyses used Cox models to investigate the potential attenuation of the treatment effect with higher baseline
heart rate on total cardiovascular events and procedures (TCVP) via introduction of an interaction term. Second-
ary analyses assessed coronary and total stroke outcomes.
Results Primary unadjusted analyses included 12,759 patients and 1,966 TCVP. At the final visit, mean heart rate reduc-
tion from baseline was 12.0 (SD 13.7) and 1.3 (SD 12.1) beats/min in atenolol- and amlodipine-based groups,
respectively. There was a reduction in TCVP in those allocated amlodipine-based therapy compared with
atenolol-based therapy (unadjusted hazard ratio: 0.81, p  0.001). This benefit was unattenuated at higher
heart rates (interaction p value  0.81). Similar results were obtained for coronary and total stroke outcomes.
Conclusions There was no evidence that the superiority of amlodipine-based over atenolol-based therapy for patients with
hypertension uncomplicated by coronary heart disease was attenuated with higher baseline heart rate. These
data suggest that, in similar hypertensive populations without previous or current coronary artery disease, higher
baseline heart rate is not an indication for preferential use of beta-blocker–based therapy. (J Am Coll Cardiol
2009;54:1154–61) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.087i
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cesting heart rate has been shown to be a significant and
ndependent predictor of all-cause and cardiovascular mor-
ality among men and women in the general population and
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009, accepted April 26, 2009.n those with various cardiovascular conditions, including
ypertension (1,2). In addition, post-exercise heart rate
ecovery (3) and heart rate variability are also associated with
ardiovascular morbidity (4). In the post-myocardial infarc-
ion (MI) setting (5) and in heart failure (6), heart-rate
eduction has been shown to be 1 of the important mech-
nisms whereby beta-blockers exert beneficial effects on
See page 1162
ardiovascular morbidity and mortality. Consequently, heart
ate is included in some risk assessment models for patients
fter acute coronary syndrome or post-MI (7,8), although
ost risk-assessment tools do not include pulse rate in the
ontext of primary prevention (9,10). Nevertheless, most
hysicians believe that a high heart rate at rest is undesir-
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September 22, 2009:1154–61 Baseline Heart Rate and BP Treatment in the ASCOT Studyble, and at least some guidelines for hypertension manage-
ent have recommended the use of beta-blockers as first-
ine therapy for those with “increased sympathetic tone” or
relative tachycardia (1,11–14). Hitherto no trial evidence
s available to confirm or refute whether such an approach
or patients with hypertension is preferable to the use of
ther agents that do not reduce the pulse rate. In the
SCOT-BPLA study (Anglo-Scandinavian Cardiac Out-
omes Trial–Blood Pressure Lowering Arm), over 19,000
ypertensive patients without prior or current coronary
rtery disease were randomized to receive an amlodipine- or
n atenolol-based regimen (15). The database for this trial
herefore afforded the opportunity to evaluate whether the
reviously reported superior effects of the amlodipine-based
egimen on cardiovascular events was attenuated among
hose with higher heart rates at baseline.
ethods
he design, conduct, and results of the ASCOT-BPLA study
ave been reported previously (15,16), and further details are
vailable on the ASCOT website. Briefly, 19,257 patients were
ecruited between February 1998 and May 2000 mainly from
amily practices in the United Kingdom, Ireland, and the
ordic Countries. Patients were randomized to either atenolol
bendroflumethiazide (atenolol-based) or amlodipine 
erindopril (amlodipine-based) antihypertensive treatment
egimens. Because ASCOT was a 2 2 factorial study, 10,240
atients were also eligible to be randomized to the lipid-
owering arm of the study (ASCOT-LLA) in which atorva-
tatin 10 mg was compared with placebo (16,17).
rial eligibility. Patients were eligible for the ASCOT-
PLA study if they had either untreated hypertension
systolic blood pressure [BP]160 mm Hg and/or diastolic
P 100 mm Hg) or treated hypertension with systolic BP
140 mm Hg and/or diastolic BP 90 mm Hg and were
ge 40 to 79 years with at least 3 of the following other
ardiovascular risk factors: male sex, age 55 years, mi-
roalbuminuria or proteinuria, smoking, total to high-
ensity lipoprotein cholesterol ratio 6, family history of
remature coronary heart disease (CHD), left ventricular
ypertrophy, other specified abnormalities on electrocardio-
ram, type 2 diabetes mellitus, peripheral arterial disease,
nd previous stroke or transient ischemic attack.
Patients who had a previous history of MI, currently
reated angina, a cerebrovascular event in the last 3 months,
asting triglyceride level 4.5 mmol/l, heart failure, uncon-
rolled arrhythmias, or any clinically important hematolog-
cal or biochemical abnormality in routine screening were
xcluded from the trial.
eart rate measurement. Heart rate and BP were mea-
ured at screening, baseline, and at every follow-up visit (6
eeks, 3 months, 6 months, and every 6 months thereafter)
ith a semi-automated device after 5 min rest in the sitting
osition. Heart rate and BP were measured 3 times at each
isit, and the mean of the last 2 readings were used for analysis. inalysis population. Patients
ere excluded if they were re-
orded as taking a beta-blocker
r any other rate-limiting antihy-
ertensive drug at screening (or
etween screening and random-
zation if documented), to ensure
hat only patients with a baseline
eart rate reading unaffected by
re-randomization antihyperten-
ive treatment were included in the analysis population. For
he majority of patients taking a calcium-channel blocker at
creening, information on the specific type of drug was not
vailable. These patients were included in the analysis
opulation, because it was most likely that they were taking
dihydropyridine (which does not slow the heart rate)
ather than verapamil or diltiazem (which do slow the heart
ate). However, sensitivity analyses excluding calcium chan-
el blockers of any type were also performed. Patients with
nown atrial fibrillation at baseline were excluded.
tatistical methods. Summary statistics of all baseline
ariables for the main analysis population were compared
ith those of the total ASCOT-BPLA population, by
llocated treatment. All analyses of antihypertensive treat-
ent groups were on an intention-to-treat basis.
Crude event rates were compared between treatment
roups for categories of baseline heart rate, for the primary
utcome “total cardiovascular event or procedure” (TCVP)
nd the secondary outcomes “nonfatal MI (including silent)
r fatal CHD” (the ASCOT-BPLA primary end point),
nd “total stroke.” Cox proportional hazards models were
sed to assess evidence for a baseline heart rate and treatment
nteraction with both unadjusted models and models with
djustment for all baseline predictors. Baseline heart rate was
rimarily modeled as a continuous variable but was also
ategorized into tertiles and into intervals of 10 beats/min.
For all 3 outcomes, baseline predictors of the outcome
ere initially identified via univariable Cox models. With a
orward stepwise approach with baseline heart rate and
reatment group (including the ASCOT-LLA treatment
roup) fixed in the models, preferred multivariable models
ere developed containing all predictors of the outcome. If
or more potential predictors were strongly related to each
ther, a choice was made about which to enter into the
ultivariable analysis on the basis of the comparative
trength of the relationships and what was useful to adjust
or on a clinical basis. An interaction between baseline heart
ate and treatment group was then added to the models, and
ll baseline variables not currently in the models were
eassessed as potential predictors.
The proportionality assumption of the Cox models was
nvestigated with Schoenfeld residuals as well as interactions
etween baseline variables and follow-up time periods. The
inearity of all continuous variables including heart rate was
lso investigated. Variables showing evidence of nonlinear-
Abbreviations
and Acronyms
BP  blood pressure
CHD  coronary heart
disease
MI  myocardial infarction
TCVP  total cardiovascular
events and proceduresty were categorized accordingly.
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Baseline Heart Rate and BP Treatment in the ASCOT Study September 22, 2009:1154–61Baseline creatinine, glucose, triglycerides, low-density
ipoprotein cholesterol, body mass index, and weekly alcohol
onsumption variables had varying degrees of missing data
3%, 10%, 9%, 11%, 1%, and 1%, respectively). The
nal multivariable Cox models reported for each outcome
xclude those patients with missing data for the included
ariables. However, analyses were repeated with multiple
mputation methods to replace missing values in the main
odels.
A number of sensitivity analyses were performed mainly to
ssess the robustness of the results by rerunning the final
ultivariable models within chosen subsets of the analysis
opulation, although it should be noted that for some analyses
he number of patients and events included was markedly
educed. Sensitivity analyses were performed: 1) excluding
atients taking calcium-channel blockers at screening; 2) exclud-
ng patients with prior stroke, transient ischemic attack,
eripheral vascular disease, or other cardiovascular disease at
aseline and then additionally excluding those with diabetes
t baseline; and 3) stratifying by randomization to the statin
r placebo arms of the trial.
All significance levels are 2-sided. Analyses were per-
ormed with the statistical software Stata version 10.0 (Stata
orp., College Station, Texas).
esults
mong 19,257 hypertensive patients randomized into
SCOT-BPLA, 12,759 were not taking a rate-limiting anti-
ypertensive drug at baseline and were therefore eligible for the
urrent analyses. The eligible subgroup were very similar to
hose in the trial overall in terms of demographic variables,
nclusion criteria, biochemical measurements, BP levels, med-
cal history, and other previous treatments (Table 1). Further-
ore, those randomized to atenolol- or amlodipine-based
reatment among the eligible subgroup did not differ im-
ortantly with regard to any of these baseline parameters.
he small differences that were apparent (e.g., serum
riglycerides and heart rate) reflect the omission of beta-
locker–treated patients in the analysis population. In sum-
ary, the population under investigation was largely male
nd white (77% and 95%, respectively) with a mean age of
3 years, among whom approximately one-quarter were
iabetic and one-third smokers. Just over one-quarter were
ot taking antihypertensive medications at baseline, and
ean BP levels were 165/95 mm Hg with a mean heart rate
f 74 beats/min.
Baseline heart rates were higher among women than
en, among smokers than nonsmokers, and among
iabetic than nondiabetic subjects. Heart rates tended to
all with increasing age but increase with increasing body
ass index, diastolic BP, reported alcohol intake, fasting
lasma triglyceride levels, and fasting glucose levels
Online Table).
By the end of follow-up overall baseline heart rate had
allen by a mean of 12.0 (SD 13.7) and 1.3 (SD 12.1) beats/min among those randomized to atenolol- and
mlodipine-based therapy, respectively. Atenolol allocation
as associated with a fall in heart rate throughout the trial,
rrespective of baseline heart rate, whereas among those
llocated amlodipine, heart rates rose among those in the
owest tertile of baseline heart rates, fell among those in the
ighest baseline tertile, and remained mainly unchanged in
he middle group.
With Cox regression, baseline heart rate did not
ignificantly predict subsequent TCVP, nonfatal MI or
atal CHD, or total stroke outcomes in univariable
unadjusted) or multivariable (adjusted for all baseline
redictors and excluding those with missing baseline
alues) analyses (Table 2). By contrast, allocation to
mlodipine-based therapy was associated with large re-
uctions in all 3 end points in univariable and multiva-
iable analyses, although this was not statistically signif-
cant for coronary events.
There was no evidence that increasing baseline heart
ate attenuated the benefit of amlodipine-based therapy
elative to atenolol-based therapy for all 3 end points in
nivariable and multivariable analyses when treating base-
ine heart rate as a continuous variable (Table 2). Similarly,
n alternative models with 5 categories of baseline heart rate
t 10-beat/min intervals, there was no apparent attenuation
f the superior impact of allocation to amlodipine-based as
ompared with atenolol-based therapy on crude event rates
ith higher baseline heart rates (Fig. 1). Moreover, the
nadjusted hazard ratios of developing each of the 3 end
oints by allocated BP treatment were unaffected by base-
ine heart rate category (data not shown). When the data
ere fully adjusted for all baseline predictors and excluding
ll patients with any missing baseline values, the results were
ssentially unchanged (Fig. 2). Consistent results were
btained with categories on the basis of tertiles of baseline
eart rate (data not shown). In addition, baseline heart rate
howed no significant association with any of the 3 end
oints in univariable or multivariable analyses when each of
he 2 BP-lowering treatment limbs was considered sepa-
ately (Table 2).
Similar results to those presented were obtained when
nalyses were repeated with multiple imputation methods to
eplace missing baseline values in the main models. Results
ere also essentially unchanged in sensitivity analyses where
ll main models were rerun after excluding patients taking
alcium channel blockers at screening. Similarly, findings
id not alter in any important way in sensitivity analyses
xcluding patients with prior stroke, transient ischemic
ttack, peripheral vascular disease, or other cardiovascular
isease at baseline or those analyses additionally removing
atients with diabetes at baseline. Sensitivity analyses of the
ain results stratifying by randomization to statin or pla-
ebo arms of the trial gave no signal that results differed
etween these 2 groups.
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September 22, 2009:1154–61 Baseline Heart Rate and BP Treatment in the ASCOT Studyiscussion
he presence of a rapid heart rate and hypertension has
een suggested to be an indication for using beta-blockers as
aseline Characteristics for Main Analysis Population andotal ASCOT-BPLA Population by Allocated Antihypertensive TreatmTable 1 B seline Characteristics for Main Analysis PopulationTotal ASCOT-BPLA Population by Allocated Antihyperte
Baseline Variables
Analysi
(n 
Atenolol
(n  6,361)
Statin trial, n (%)
Yes: placebo 1,696 (27)
Yes: statin 1,712 (27)
No 2,953 (46)
Patient characteristics
Heart rate, beats/min, mean (SD) 73.8 (12.1)
Age in yrs, mean (SD) 63.0 (8.6)
Male, n (%) 4,893 (77)
Body mass index in kg/m2, mean (SD)† 28.5 (4.4)
Current smoker, n (%) 2,156 (34)
Diabetic, n (%) 1,761 (28)
Systolic BP, mm Hg, mean (SD) 164.5 (17.5)
Diastolic BP, mm Hg, mean (SD) 94.8 (10.5)
Alcohol, U/week, mean (SD)† 7.9 (11.5)
Left ventricular hypertrophy, n (%) 1,306 (21)
Metabolic syndrome, n (%) 2,529 (40)
Ethnicity, n (%)
White/Europid 6,041 (95)
African 178 (3)
Mixed/other/Oriental 62 (1)
South Asian 80 (1)
Medical history, n (%)
Family coronary artery disease 1,755 (28)
Stroke/TIA 645 (10)
Vascular disease* 1,025 (16)
Other cardiovascular disease 315 (5)
Noncardiovascular concomitant disease 3,815 (60)
Biochemical results, mmol/l, mean (SD)
HDL cholesterol 1.3 (0.4)
Total cholesterol 5.9 (1.1)
Fasting triglycerides† 1.8 (1.0)
LDL cholesterol† 3.8 (1.0)
Fasting glucose† 6.3 (2.2)
Creatinine† 98.1 (16.8)
Baseline medical treatment, n (%)
Aspirin 1,141 (18)
Lipid-lowering 625 (10)
At least 1 antihypertensive drug 4,578 (72)
Beta-blocker —
Diuretic 1,652 (26)
Calcium-channel blocker 2,011 (32)
Angiotensin-converting enzyme inhibitor 1,903 (30)
Angiotensin receptor blocker 486 (8)
Alpha blocker 284 (4)
Other 44 (1)
Stroke/transient ischemic attack (TIA) or peripheral vascular disease. †Missing values: for analy
,210 (9%); low-density lipoprotein (LDL) cholesterol  1,422 (11%); fasting glucose  1,237 (10
ASCOT-BPLA  Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm; BPn initial antihypertensive therapy (1,11–14). However, tefore this analysis there were no data available from
andomized controlled trials to assess the impact of this
dvice on patient outcomes (12). In this large substudy of
he ASCOT study, as in the main study, amlodipine-based
Group
Treatment Group
lation
9)
Total ASCOT-BPLA Population
(n  19,257)
Amlodipine
(n  6,398)
Atenolol
(n  9,618)
Amlodipine
(n  9,639)
1,727 (27) 2,562 (27) 2,544 (26)
1,740 (27) 2,570 (27) 2,564 (27)
2,931 (46) 4,486 (47) 4,531 (47)
73.8 (12.1) 71.8 (12.6) 71.9 (12.7)
62.8 (8.6) 63.0 (8.5) 63.0 (8.5)
4,910 (77) 7361 (77) 7,381 (77)
28.5 (4.5) 28.7 (4.5) 28.7 (4.5)
2,212 (35) 3,109 (32) 3,168 (33)
1,729 (27) 2,572 (27) 2,565 (27)
164.5 (17.6) 163.9 (18.0) 164.1 (18.1)
95.2 (10.5) 94.5 (10.4) 94.8 (10.4)
8.0 (11.6) 7.9 (11.7) 8.0 (11.6)
1,347 (21) 2,076 (22) 2,091 (22)
2,472 (39) 4,043 (42) 4,048 (42)
6,065 (95) 9,170 (95) 9,187 (95)
168 (3) 240 (2) 223 (2)
69 (1) 94 (1) 97 (1)
96 (2) 114 (1) 132 (1)
1,817 (28) 2,629 (27) 2,655 (28)
673 (11) 1,063 (11) 1,050 (11)
1,016 (16) 1,586 (16) 1,546 (16)
319 (5) 486 (5) 533 (6)
3,763 (59) 5,741 (60) 5,651 (59)
1.3 (0.4) 1.3 (0.4) 1.3 (0.4)
5.9 (1.1) 5.9 (1.1) 5.9 (1.1)
1.8 (1.0) 1.9 (1.0) 1.8 (1.0)
3.8 (1.0) 3.8 (1.0) 3.8 (1.0)
6.2 (2.2) 6.2 (2.1) 6.2 (2.1)
97.9 (16.9) 98.56 (16.8) 98.5 (16.8)
1,160 (18) 1,837 (19) 1,851 (19)
669 (10) 1,004 (10) 1,046 (11)
4,566 (71) 7,793 (81) 7,798 (81)
— 3,072 (30) 3,086 (32)
1,699 (27) 2,764 (29) 2,726 (28)
1,935 (30) 2,791 (29) 2,724 (28)
1,983 (31) 2,437 (25) 2,535 (26)
476 (7) 616 (6) 602 (6)
296 (5) 415 (4) 421 (4)
45 (1) 125 (1) 132 (1)
ulation  body mass index  2 (1%); units of alcohol/week  5 (1%); fasting triglycerides 
atinine  407 (3%).
pressure; HDL  high-density lipoprotein.entand
nsive
s Popu
12,75
sis popherapy was superior at reducing cardiovascular events
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Baseline Heart Rate and BP Treatment in the ASCOT Study September 22, 2009:1154–61ompared with atenolol-based therapy. Atenolol-based
herapy reduced heart rate more effectively than amlodipine
t all baseline heart rates. Nevertheless, in both unadjusted
nd adjusted analysis, there was no tendency toward a
eduction in the advantage of amlodipine- over atenolol-
ased therapy with higher baseline heart rates even in the
ighest categories of heart rate. Clearly, the study had
educed power to assess the impact of baseline heart rate on
ndividual components of TCVP such as CHD and total
troke, but for these end points the results also showed no
endency for higher pulse rates to be associated with an
ttenuation of the superiority of amlodipine-based therapy.
onsequently, our analysis does not support the specific use
f atenolol as initial antihypertensive therapy in those with
r without a high baseline heart rate, and more generally it
eems reasonable to conclude, pending contradictory evi-
ence, that a higher heart rate should not be used as the
asis for selecting a beta-blocker in hypertensive patients
nless specific indications such as heart failure or ischemic
eart disease apply.
tudy limitations. First, the study hypothesis was devel-
ped after the conduct of the trial. Nevertheless, in the
ultiple analyses with different end points we found no
vidence of an interaction between therapies based on
tenolol or amlodipine and heart rate, and furthermore,
here was no evidence from adjusted analyses that age or sex
nfluenced the lack of effect of heart rate on the outcomes of
tenolol- or amlodipine-based therapy. Second, the analyses
ox Model Results Relating to Baseline Heart Rate and Allocatedreatment Group for A l 3 Ou comes, Both Unadjusted and AdjusteTable 2 Cox Mod l Res lts Relati g to Baseline Heart Rate anTreatment Group for All 3 Outcomes, Both Unadjusted
Models
Total CV Events and Procedures
(n  12,759, d  1,966)*
HR 95% CI p Value
Unadjusted
Allocated treatment
Amlodipine† 0.81 0.74–0.88 0.001
Baseline heart rate (per 5 beats/min)
Overall 0.99 0.97–1.01 0.43
Atenolol 0.99 0.97–1.02 0.69
Amlodipine 0.99 0.96–1.02 0.50
Interaction p value‡ — — 0.81
Adjusted§
Allocated treatment
Amlodipine† 0.80 0.72–0.87 0.001
Baseline heart rate (per 5 beats/min)
Overall 1.00 0.98–1.02 0.69
Atenolol 1.00 0.98–1.03 0.81
Amlodipine 1.01 0.98–1.04 0.72
Interaction p value‡ — — 0.91
Due to missing values of some baseline variables, n  11,520, d  1,749; n  11,165, d  529
yocardial infarction (MI) (including silent) and fatal coronary heart disease (CHD), and total strok
reatment and baseline heart rate. §For each of the 3 outcomes, in addition to the heart rate and
ipid-lowering arm (LLA) treatment group, age, current smoker, previous vascular disease, sex,
riglyceride, ethnicity, previous antihypertensive treatment, left ventricular hypertrophy, noncard
reatment group, age, current smoker, previous vascular disease, sex, systolic BP, glucose, total c
ge, current smoker, previous stroke/TIA, systolic BP, glucose, other cardiovascular disease, prev
HR  hazard ratio; d  number of events; other abbreviations as in Table 1.nvolved a subsample (albeit large) of the overall trial ropulation, due to our exclusion of patients treated with
eart rate-lowering drugs before the start of the trial.
lthough this exclusion criterion was necessary to assess
true” baseline heart rate, it is theoretically possible that it
ight also have created a bias by excluding patients with
ore rapid baseline heart rates who might have benefited
ore from rate-limiting therapy. However, among the total
SCOT population, which included patients taking pre-
xisting heart rate-lowering therapy, the superiority of
mlodipine-based therapy was not diluted compared with
he benefits shown in these analyses (15). Third, there were
nly approximately 300 patients in the ASCOT study with
aseline heart rates of over 100 beats/min, which limited our
ower to evaluate this group. However, approximately 1,100
atients had a baseline heart rate of over 90 beats/min, and
o signal of an attenuated differential treatment effect was
pparent in this group (Fig. 2). It is possible that some with
very rapid heart rate (e.g., those with a heart rate
ignificantly 100 beats/min) might derive specific advan-
ages from beta-blocker–based therapy. Finally, it is possi-
le that heart rate at baseline might not truly reflect the
sual heart rate for an individual entering the trial; however,
eart rates at multiple visits before randomization were
nfortunately not available in the ASCOT dataset to allow
n evaluation of this potential shortcoming.
Baseline heart rate has been reported as a significant
redictor of various cardiovascular outcomes in some but
ot all studies (1,2,18). In the ASCOT study, baseline heart
All Baseline Predictorsocated
Adjusted for All Baseline Predictors
Nonfatal MI and Fatal CHD
(n  12,759, d  607)*
Total Stroke
(n  12,759, d  490)*
HR 95% CI p Value HR 95% CI p Value
0.88 0.75–1.03 0.11 0.74 0.62–0.88 0.001
1.03 0.99–1.06 0.10 1.01 0.97–1.04 0.70
1.03 0.98–1.07 0.24 1.01 0.97–1.06 0.60
1.03 0.98–1.08 0.25 1.00 0.95–1.06 0.99
— — 0.98 — — 0.73
0.86 0.73–1.02 0.09 0.75 0.62–0.91 0.003
1.02 0.98–1.06 0.27 1.02 0.98–1.06 0.43
1.02 0.97–1.07 0.45 1.03 0.98–1.08 0.31
1.02 0.97–1.08 0.40 1.00 0.94–1.06 0.99
— — 0.91 — — 0.51
 11,163, d  419, for the adjusted models of the total cardiovascular events and procedures,
me models, respectively. †Atenolol is reference group. ‡p value for interaction between allocated
treatment group variables there was adjustment for: total cardiovascular events and procedures:
blood pressure (BP), glucose, other cardiovascular disease, total cholesterol, HDL cholesterol,
lar concomitant disease, and previous aspirin therapy; MI (including silent) and fatal CHD: LLA
rol, HDL cholesterol, triglyceride, ethnicity, and creatinine; and total stroke: LLA treatment group,
tihypertensive treatment, creatinine, and alcohol.d forAll
and
; and n
e outco
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systolic
iovascu
holesteate did predict all-cause, noncardiovascular, and cardiovas-
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Figure 1 Crude Event Rates by Allocated
Treatment Group and Baseline Heart Rate Group
Crude event rates/100 person-years and 95% confidence intervals (CIs) (n 
12,759): (A) total cardiovascular events and procedures (1,966 events); (B)
nonfatal myocardial infarction (including silent) and fatal coronary heart dis-
ease (607 events); (C) total stroke (490 events). bpm  beats/min.Heart rate categories
<60 bpm
60 to <70 bpm
70 to <80 bpm
80 to <90 bpm
90+ bpm
Overall
No. Events/Patients
Atenolol Amlodipine
116/640
277/1689
287/1799
185/1060
91/544
956/5732
110/678
203/1596
245/1847
166/1115
69/552
793/5788
    Interaction
      p value* = 0.910.5 0.8 1 1.2
          Amlodipine better        Atenolol better  
 
Hazard ratio and 95% CI (log scale)
A
Heart rate categories
<60 bpm
60 to <70 bpm
70 to <80 bpm
80 to <90 bpm
90+ bpm
Overall
No. Events/Patients
Atenolol Amlodipine
26/616
83/1643
88/1739
58/1035
26/521
281/5554
30/658
59/1546
78/1796
62/1078
19/533
248/5611
    Interaction
      p value* = 0.910.5 0.8 1 1.2 1.6
      Amlodipine better      Atenolol better 
 
Hazard ratio and 95% CI (log scale)
B
Heart rate categories
<60 bpm
60 to <70 bpm
70 to <80 bpm
80 to <90 bpm
90+ bpm
Overall
No. Events/Patients
Atenolol Amlodipine
27/616
65/1643
70/1739
49/1034
25/521
236/5553
32/658
40/1547
59/1795
37/1078
15/532
183/5610
    Interaction
      p value* = 0.510.5 0.8 1 1.2 1.6
      Amlodipine better      Atenolol better  
 
Hazard ratio and 95% CI (log scale)
C
Figure 2 Hazard Ratios for Allocated Antihypertensive
Treatment by Baseline Heart Rate Group
Hazard ratios and 95% CIs after adjusting for all baseline predictors and
excluding patients with missing baseline values: (A) total cardiovascular
events and procedures outcome; (B) nonfatal myocardial infarction (including
silent) and fatal coronary heart disease outcome; (C) total stroke outcome.
*Interaction p value is for interaction between continuous heart rate and allo-
cated treatment group. Abbreviations as in Figure 1.
c
n
6
w
a
t
n
W
e
c
A
o
c
i
o
C
c
d
M
a
h
d
f
i
e
d
w
h
h
v
T
b
v
r
p
H
l
t
h
C
T
t
w
r
d
h
(
t
a
t
a
R
I
L
K
R
1
1
1
1
1
1
1
1
1
1160 Poulter et al. JACC Vol. 54, No. 13, 2009
Baseline Heart Rate and BP Treatment in the ASCOT Study September 22, 2009:1154–61ular mortality but not nonfatal cardiovascular events (data
ot shown). Neither baseline nor attained heart rate at the
-week interval in this subpopulation of the ASCOT study
as associated with the TCVP or total stroke outcomes
fter multivariable adjustment, but there was some sugges-
ion that heart rate at 6 weeks was associated with the
onfatal MI and fatal CHD outcome (data not shown).
hy heart rate, either in the whole population or within
ach of the 2 BP-lowering treatment groups, was not
onsistently associated with all cardiovascular events in the
SCOT study is not clear, but it is possible that the impact
f heart rate was obscured by more critical effects on
ardiovascular outcomes such as large and rapid BP lower-
ng and large changes in lipid profiles (15,17).
The current findings in the ASCOT study might well
nly relate to patients with hypertension uncomplicated by
HD. Beta-blocker therapy remains the initial therapeutic
hoice for the control of symptoms of ischemic heart
isease, and to reduce mortality in patients who have had an
I and for those who have heart failure, beta-blockers are
critically useful add-on therapy. Indeed, in the setting of
eart failure and MI, a rapid baseline heart rate and greater
ecline in heart rate are both associated with greater benefits
rom beta-blockade (1,12). It is possible that the reduction
n myocardial oxygen consumption or antiarrhythmic prop-
rties of beta-blockers play a more substantive role in
etermining outcomes in these situations than in patients
ith hypertension. However, an analysis of the effect of
eart rate in patients with ischemic heart disease and
ypertension who were randomized to receive atenolol or
erapamil in the INVEST (International Verapamil-
randolapril Study) was recently reported (19). Although
oth baseline and on-treatment heart rate predicted cardio-
ascular outcomes in this high-risk population, the greater
eduction in heart rate with atenolol compared with vera-
amil did not translate into fewer cardiovascular events.
ence, on the basis of these results, the superiority of
owering heart rate pharmacologically with a beta-blocker in
hose with hypertension and stable ischemic heart disease
as not been demonstrated.
onclusions
hese analyses provide no evidence that atenolol-based
herapy is superior to amlodipine-based therapy for patients
ith hypertension uncomplicated by CHD across the wide
ange of baseline heart rates observed in the ASCOT
atabase. Pending further information—which could per-
aps be gleaned from other studies, such as the LIFE
Losartan Intervention For Endpoint reduction in Hyper-
ension) study (20)—beta-blocker–based therapies are not
ppropriate to select as initial therapy for hypertension on
he basis of a higher heart rate unless congestive heart failure
nd/or symptomatic ischemic heart disease coexist.eprint requests and correspondence: Prof. Neil R. Poulter,
nternational Centre for Circulatory Health, Imperial College
ondon, 59 North Wharf Road, London W2 1PG, United
ingdom. E-mail: n.poulter@imperial.ac.uk.
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APPENDIX
or the supplementary table showing the mean baseline heart rate (and
tandard deviation) for various categorizations of baseline variables, by
llocated antihypertensive treatment group, please see the online version
f this article.
